Under construction – not a live service

Skip to content

Frontlight Research

Institution

East Carolina University

Greenville, United StateseducationWebsite

Also known as: East Carolina · Universidad del Este de Carolina · ECU

140running trials
46closed trials
0trials confirmed by the site in the last 60 days
–languages not stated

The site has not confirmed any trial yet.

Running trials

Recruiting
The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma
NCT07560826· Phase 2· Source
Recruiting
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
NCT07195591· Phase 3· Source
Recruiting
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
NCT06890338· Phase 2· Source
Recruiting
Optimizing the AYA Survivors' Coping and Emotional Needs Toolkit
NCT07173205· Source
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
NCT07190222· Phase 3· Source
Recruiting
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
NCT06824168· Phase 2· Source
Recruiting
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
NCT06699849· Phase 2· Source
Recruiting
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
NCT06577441· Phase 2· Source
Recruiting
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
NCT06317662· Phase 2· Source
Recruiting
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
NCT06672146· Phase 2· Source
Recruiting
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
NCT06401330· Phase 3· Source
Recruiting
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
NCT06612268· Phase 3· Source
Recruiting
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
NCT06717347· Phase 3· Source
Recruiting
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
NCT06609226· Phase 3· Source
Recruiting
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT06588478· Phase 2· Source
Recruiting
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
NCT06439082· Phase 3· Source
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386· Phase 3· Source
Recruiting
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
NCT06317649· Phase 2· Source
Recruiting
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
NCT05554406· Phase 2· Source
Recruiting
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
NCT05554393· Phase 2· Source
Recruiting
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
NCT06546670· Phase 1/2· Source
Active, not recruiting
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06508658· Phase 3· Source
Recruiting
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
NCT06205485· Phase 3· Source
Recruiting
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
NCT06064097· Phase 2· Source
Recruiting
Physical Activity to Mitigate PreEclampsia Risk
NCT06319014· Source
Recruiting
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
NCT05564390· Phase 2· Source
Active, not recruiting
A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
NCT06226571· Phase 1· Source
Recruiting
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
NCT05485961· Phase 2/3· Source
Enrolling by invitation
A Registry Based Collaborative to Measure Efficiency, Effectiveness, and Safety of Farapulse PFA Technology for AF
NCT06335082· Source
Recruiting
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
NCT06172296· Phase 3· Source
Active, not recruiting
RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
NCT05966194· Phase 2· Source
Recruiting
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
NCT05939414· Phase 3· Source
Recruiting
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
NCT06091865· Phase 3· Source
Recruiting
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
NCT05943535· Phase 3· Source
Recruiting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· Phase 3· Source
Recruiting
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
NCT05673148· Phase 2· Source
Recruiting
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807· Phase 3· Source
Recruiting
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
NCT05675410· Phase 3· Source
Recruiting
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
NCT04124120· Source
Recruiting
Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT)
NCT06071377· Source
Recruiting
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
NCT05382338· Phase 3· Source
Active, not recruiting
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05578976· Phase 3· Source
Recruiting
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
NCT05677490· Phase 3· Source
Active, not recruiting
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response
NCT05610163· Phase 2/3· Source
Active, not recruiting
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
NCT05481151· Phase 3· Source
Active, not recruiting
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
NCT05482971· Phase 2· Source
Active, not recruiting
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
NCT05409066· Phase 3· Source
Active, not recruiting
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
NCT05243797· Phase 3· Source
Enrolling by invitation
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
NCT04905693· Phase 3· Source
Recruiting
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
NCT05281471· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Childhood cancers21 recruiting
Acute myeloid leukemia10 recruiting
Acute lymphoblastic leukaemia7 recruiting
Myelodysplastic syndromes5 recruiting
Ovarian cancer5 recruiting
Chronic lymphocytic leukaemia4 recruiting
Colorectal cancer4 recruiting
Myeloproliferative neoplasms4 recruiting
Sickle cell disease4 recruiting
Diffuse large B-cell lymphoma3 recruiting
Kidney cancer3 recruiting
Lung cancer3 recruiting
Multiple myeloma3 recruiting
Sarcoma3 recruiting
Atrial fibrillation2 recruiting
Chronic myeloid leukaemia2 recruiting
Coronary artery disease2 recruiting
Gastric and esophageal cancer2 recruiting
Idiopathic pulmonary fibrosis2 recruiting
Melanoma2 recruiting
Neuroblastoma2 recruiting
Obesity2 recruiting
Pancreatic cancer2 recruiting
Prostate cancer2 recruiting
Amyloidosis1 recruiting
Bladder cancer1 recruiting
Chronic kidney disease1 recruiting
COPD1 recruiting
Follicular lymphoma1 recruiting
Glioblastoma1 recruiting
High blood pressure1 recruiting
Hodgkin lymphoma1 recruiting
Mantle cell lymphoma1 recruiting
Metastatic breast cancer1 recruiting
Neuroendocrine tumours1 recruiting
Pulmonary arterial hypertension1 recruiting
Stroke1 recruiting
Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

Recruiting
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07214779· Phase 3· Source
Recruiting
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
NCT06609226· Phase 3· Source
Completed
Evaluating Procedures for a Study of the AYA Survivors Coping and Emotional Needs Toolkit
NCT06420193· Source
Completed
RECOVER-SLEEP: Platform Protocol
NCT06404086· Phase 2· Source
Completed
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
NCT06208306· Phase 3· Source
Terminated
A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382
NCT06032546· Phase 2· Source
Completed
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
NCT05776225· Source
Completed
RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms
NCT05595369· Phase 2· Source
Terminated
AB1 in Adult Patients With Sickle Cell Disease (SCD)
NCT05261711· Phase 1/2· Source
Completed
Research Study Investigating How Well NDec Works in People With Sickle Cell Disease
NCT05405114· Phase 2· Source
Terminated
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations
NCT05267106· Phase 2· Source
Completed
A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease
NCT04987489· Phase 2· Source
Completed
A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)
NCT05075824· Phase 2· Source
Terminated
Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD
NCT04930445· Source
Terminated
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
NCT04984811· Phase 2· Source
Recruiting
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
NCT04657822· Phase 4· Source
Completed
DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)
NCT04825834· Source
Completed
Cognitive Behavioral Therapy and Real-Time Pain Management Intervention for Sickle Cell Via Mobile Applications
NCT04419168· Source
Completed
Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)
NCT04084080· Phase 3· Source
Completed
Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia
NCT03836209· Phase 2· Source
Terminated
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
NCT03926624· Phase 3· Source
Completed
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
NCT03626688· Phase 3· Source
Completed
Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients
NCT03474965· Phase 2· Source
Completed
North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2
NCT03548779· Source
Completed
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
NCT03092674· Phase 2/3· Source
Completed
Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer
NCT03223753· Phase 3· Source
Completed
A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)
NCT02932410· Phase 3· Source
Completed
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
NCT02828358· Phase 2· Source
Terminated
Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis
NCT02859896· Phase 3· Source
Completed
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
NCT02180867· Phase 2/3· Source
Completed
Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas
NCT01793233· Source
Completed
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
NCT01553149· Phase 2· Source
Completed
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
NCT02883049· Phase 3· Source
Completed
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile
NCT01454297· Source
Completed
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
NCT01190930· Phase 3· Source
Completed
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
NCT01013649· Phase 3· Source
Completed
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
NCT00980460· Phase 3· Source
Completed
Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00557193· Phase 3· Source
Completed
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
NCT00379340· Phase 3· Source
Completed
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
NCT00408005· Phase 3· Source
Completed
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor
NCT00352534· Phase 3· Source
Completed
Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease
NCT00107198· Phase 2· Source
Completed
Study of Kidney Tumors in Younger Patients
NCT00898365· Source
Completed
Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
NCT00217737· Phase 3· Source
Completed
Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma
NCT00085735· Phase 3· Source
Completed
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
NCT00904241· Source

Trial sites

Institution data: ROR 01vx35703 (CC0-1.0)Updated 7 Nov 2026

Report an error